At the Virginia Institute for Psychiatric and Behavioral Genetics, consistent with the School of Medicine Diversity, Equity, and Inclusion statement, we strive to conduct innovative, ethical research of the highest quality across diverse populations, while fostering an inclusive, collaborative, and unprejudiced1,2 environment in which to educate the next generation of scientists. Accordingly, we, the members of VIPBG, endeavor to create and nurture an environment where all voices are heard. Inclusivity, diversity, equity, and access across personal, scientific, and organizational domains are valued and promoted. These efforts are ongoing and active, requiring continual self-reflection, dialogue, evaluation, and improvement.
Diversity encompasses all aspects of race, ethnicity, gender, gender identity, age, sexual orientation, ability, socio-economic status, religious beliefs, geographic region, nationality, language, political beliefs, ideas, and values. Collaborative groups who embrace inclusivity benefit from varied perspectives. Indeed, having diversity within a team increases the likelihood of generating prolific, innovative, and impactful scientific output3,4,5.
We recognize and condemn the practice of eugenics and the historical misuse of psychiatric and behavioral genetics research to justify racist and ableist policies and atrocities. Our educational mission includes reflecting on this past and implementing equitable and just paths forward. As researchers we strive to achieve parity by including diverse samples, and by developing and applying methods to best understand and improve population health for all.
IDEA-Related Funding Opportunities
id
Sponsor
Identifier
Title
Expires
Link
Summary
1
NIH
NOT-OD-22-178
Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan
2025-05-08
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved.
2
NIH
NOT-MD-22-012
Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations
2025-08-08
This Notice is a reissue of and supersedes NOT-MD-19-001 - Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations which calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.
3
NIH
RFA-EY-21-003
BRAIN Initiative-Related Research Education: Short Courses (R25 Clinical Trial Not Allowed)
2024-02-16
The purpose of this FOA is to encourage applications for the continuation of ongoing and creation of new courses for skills development that will significantly advance the educational goals of the BRAIN Initiative as described in The BRAIN Initiative®2.0: From Cells to Circuits, Toward Cures including neuroethics and opportunities to increase the workforce diversity in BRAIN Initiative research areas.
4
NIH
RFA-HG-21-041
New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)
2024-02-23
This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome Research Institute (NHGRI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and All of Us Research Program (All of Us). This program is intended to support Early Stage Investigators and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.
5
NIH
PAR-22-072
Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01 Clinical Trial Not Allowed)
2024-05-08
The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.
6
NIH
PAR-21-325
Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)
2024-09-08
The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research. This FOA provides support to complete a mental health-related doctoral research project and includes funds not readily available in NRSA predoctoral (F31) awards, which limit support to stipends, tuition and fees, and institutional allowance.
7
NIH
PAR-21-271
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
2024-09-08
The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas.
8
NIH
PAR-21-273
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))
2024-09-08
The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas.
9
NIH
PAR-21-313
Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)
2024-09-08
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI).
10
NIH
PAR-22-097
Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
2024-12-10
This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system function and disorders throughout life, relevant to LMICs.
11
NIH
PAR-22-098
Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
2024-12-10
This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, piloting innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system-related function and disorders throughout life, relevant to LMICs.
12
NIH
NOT-MH-22-045
Notice of Special Interest (NOSI): Secondary Analysis of Posttraumatic Psychopathology Data
2025-01-08
NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to analyze existing and accumulating data to aid in refining phenotypes of posttraumatic psychopathology(ies), markers of onset and change, and risk detection. NIMH is also interested in research using available data to identify potential prevention and treatment targets and to advance and refine measurement and validation of potential novel targets for future development in experimental therapeutics research.
13
NIH
RFA-DA-23-026
NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio.. This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders.
14
NIH
RFA-DA-23-031
NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio.. This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders.
15
NIH
RFA-DA-23-013
NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities insubstance use, addiction, and related health consequences, including HIV. Applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities.
16
NIH
RFA-DA-23-032
NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities insubstance use, addiction, and related health consequences, including HIV. Applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities.
17
NIH
RFA-DA-23-053
HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
2024-03-21
There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels.
18
NIH
RFA-DA-23-054
HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
2024-03-21
There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels.
19
NIH
RFA-DA-23-023
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional)
2024-11-15
The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
20
NIH
RFA-DA-23-024
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional)
2024-11-15
The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
21
NIH
RFA-DA-23-028
NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.
22
NIH
RFA-DA-23-029
NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.
23
NIH
RFA-MH-22-185
NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
2025-06-21
The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders.
24
NIH
RFA-HG-22-026
Diversity Centers for Genome Research (U54 Clinical Trials Optional)
2024-06-24
The Diversity Center for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. Each DCGR award will support a multi-investigator, interdisciplinary team to develop 2-3 interrelated, innovative genomic research projects. Each project should address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics; ethical, legal, and social implications of genomic research; and/or genomics and health equity.
25
NIH
RFA-HG-22-027
Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional)
2024-06-24
The full-scale Diversity Centers for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. The purpose of this FOA is to call for applications for UG3/UH3 cooperative agreements to support the development and planning for a multi-investigator, interdisciplinary team to develop administrative, genomic workforce development and community engagement cores and 2-3 interrelated, innovative genomic research projects.
26
NIH
PAR-23-030
Leading Equity and Diversity in the Medical Scientist Training Program (LEAD MSTP)(T32)
2025-01-27
The goal of the Leading Equity and Diversity in the Medical Scientist Training Program (LEAD MSTP) is to develop a diverse pool of highly trained clinician-scientist leaders available to meet the Nation’s biomedical research needs by providing support for dual-degree clinician scientist training at institutions that have historically not been well represented among NIGMS-funded MSTPs.
27
NIH
NOT-OD-23-002
Notice of Special Interest (NOSI): Administrative Supplements to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility (DEIA) Mentorship
-0001-11-30
The participating Institutes and Centers (ICs) are inviting applications to support administrative supplements to existing NIH awards to support scientists who have demonstrated compelling commitments and contributions to mentorship and enhancing diversity, equity, inclusion, and accessibility (DEIA) in the biomedical sciences.
28
NIH
PAR-23-037
Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
2026-05-07
The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies that will be conducted using NICHD-supported network infrastructure. One of the goals of this FOA is to facilitate greater involvement of diverse populations in multisite studies.
29
NIH
RFA-DA-23-062
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional)
2024-11-14
The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
30
NIH
RFA-DA-23-061
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional)
2024-11-14
The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
31
NIH
PAR-23-075
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
2026-01-07
The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects.
32
NIH
NOT-DA-23-013
Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV
-0001-11-30
The purpose of this Funding Opportunity Announcement (FOA) is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications, which are commonly affected by HIV and substance use and lead to neuropathology and neurocognitive dysfunction.
33
NIH
PAR-23-076
NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
2025-11-18
This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA’s mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. It is expected that a Center will transform the scientific fields of focus. New and creative directions, but not incremental work, should be the focus of Center activities. The P50 Center of Excellence is expected to mentor and foster the career development of new and early career investigators by providing meaningful roles in the Center projects and research activities. The overarching goal of this program is to create NIDA Centers that will serve as the national resources to advance research relevant to substance use and SUDs by facilitating collaborations, sharing of data, research tools and reagents.
34
NIH
PAR-23-049
NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
2025-11-17
NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance and extend existing research relevant to substance use/misuse and addiction and HIV. Centers are expected to transform the scientific field of study by facilitating research, providing administrative support and a rigorous research climate that promotes new and creative directions. Incremental work should not be the focus of Center activities. Applications responding to this Funding Opportunity Announcement (FOA) are strongly encouraged to integrate and promote research in the funded projects and support interdisciplinary collaborations.Centers also must focus on providing research opportunities and experiences to new and early career investigators from diverse backgrounds, including those from underrepresented populations or institutions, facilitating collaborations, and linking and sharing data, research findings and resources to achieve the goals of the program.
35
NIH
NOT-MH-23-140
Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services
-0001-11-30
The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women’s Health (ORWH) are issuing this Notice of Special Interest (NOSI) to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.
36
NIH
PAR-23-050
Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
2026-01-07
This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined health disparity populations. (see https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.
37
NIH
PAR-23-087
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
2025-06-20
The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates.
38
NIH
PAR-23-092
Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)
2024-07-05
This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span.
39
NIH
NOT-MD-23-001
Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience Pilot Research Projects at NIMHD-Funded Research Centers in Minority Institutions (RCMI)
-0001-11-30
This Notice of Special Interest (NOSI) invites applications for administrative supplements to NIMHD Research Centers in Minority Institutions (RCMI) U54 awards to support pilot research projects led by early-stage investigators (ESIs) and new investigators (NIs) focused on research on substance use, addiction, and/or neuroscience, as a bridge to independently funded careers. It is expected that pilot project PIs will work with their institutions to prepare and submit follow-up research grant or career development applications to NIH based on the research supported by these supplemental funds.
40
NIH
NOT-DA-24-001
Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine.
-0001-11-30
Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defining effects of human genetic variants on HIV treatment toxicity, efficacy, and pharmacokinetics has far-reaching implications. Substances of abuse (opioid, stimulants, nicotine, anxiolytics, alcohol, etc.) and its treatments (methadone, buprenorphine, extended naltrexone, etc.) may interact with ART, altering its bioavailability, its safety, and its efficacy. It is known that nevirapine and efavirenz increase methadone clearance. New evidence demonstrates that variabilities in responses to ART depend in part on genetic variants for certain drugs of abuse and its therapies. For instance, a NR1I3 gene variant affected methadone clearance only in those taking efavirenz. Two other genetic variants in the ABCB1 and CYP2B6 genes decreased methadone clearance. More research, though, is necessary to better understand the role of pharmacogenomics in people with HIV (PLWH) with substance use disorders (SUD).
41
NIH
NOT-GM-23-028
Notice of Special Interest (NOSI) in Applications to Support Training, Workforce Development, and Diversity Conferences (R13)
-0001-11-30
This Notice of Special Interest (NOSI) encourages applications for support of conferences focused on evidence-informed interventions to enhance training, workforce development and diversity in the biomedical research enterprise.
42
NIH
RFA-DA-24-037
Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
2024-11-15
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.
43
NIH
PAR-23-124
Genomic Community Resources (U24 Clinical Trial Not Allowed)
2026-01-25
To facilitate genomic research and the dissemination of its products, NHGRI supports both new and existing genomic resources of demonstrated broad value to the research community. Awards under this FOA will support the development and distribution of high-value genomic resources valuable for both basic and clinical genomics research.
44
NIH
RFA-DA-24-001
Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
2025-08-13
This Notice of Funding Opportunity (NOFO) invites grant applications aimed at elucidating pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms in the presence of addictive substances, with emphasis on genetic, epigenetic and neuroimmune mechanisms at the single cell to neural circuit levels.
45
NIH
PAR-23-118
National Centers for Cryoelectron Microscopy (R24 Clinical Trial Not Allowed)
2024-06-28
This initiative will support national service centers for molecular structure determination by high resolution cryoelectron microscopy (cryoEM). The centers will provide access to state-of-the-art equipment, technical support, and training for the production and analysis of high-resolution data and offer equal-opportunity nationwide access to services through an open application process.
46
NIH
PAR-23-263
NIMH Mentoring Networks for Mental Health Research Education (R25 Clinical Trial Not Allowed)
2025-05-25
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
47
NIH
PAR-23-265
NIMH Short Courses for Mental Health Related Research (R25 -Independent Clinical Trial Not Allowed)
2025-05-25
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
48
NIH
NOT-AA-23-003
Notice of Special Interest: Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence
-0001-11-30
In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result ofthe global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA’s interest in addressingthe critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skillsshown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term “domestic violence” will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).
49
NIH
NOT-HD-23-006
Notice of Special Interest (NOSI): Climate Change and Health Administrative Supplements
-0001-11-30
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), in partnership with the National Institute of Environmental Health Science (NIEHS), Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI), and National Institute of Allergy and Infectious Disease (NIAID) is involved with an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health equity of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, and nations around the world. As a part of this CCHI, the participating Institutes and Centers (ICs) invite applications to supplement active NIH awards to seed new activities and partnerships in climate change and health (CCH) research and research training. We particularly invite applications for supplements to grants that are not currently focused on CCH but wish to include CCH measures and outcomes within the scope of their current research and training specific aims, for example by extending CCH metrics to existing cohorts and studies or by supporting additional CCH areas within broadly defined Center or Hub grants. We will also accept supplement applications to grants already focused on CCH, for example to expand their activities to new populations, modeling activities, exposure measurements, and health outcomes. As administrative supplements, the activities proposed must be within the scope of the parent grant specific aims. Applicants are encouraged to bring in new partners, as needed, who will provide climate science and related expertise and begin to build multidisciplinary teams for future research in this area.
50
NIH
PAR-23-131
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
2026-05-07
The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.
51
NIH
PAR-23-130
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
2026-05-07
The over-arching intent of this solicitation is to: (1) enrich and expand the research community in CCH to include new researchers from multiple disciplines, both in the US and in low- and middle-income countries (LMICs) globally; and (2) conduct research that will create new knowledge to reduce or mitigate health threats attributable to climate change across the lifespan and build health resilience or develop adaptation mechanisms for individuals, communities, and nations around the world, especially among those at increased risk from, or disproportionately affected by, the impacts of climate change. Awardees are expected to seek competing support to continue promising leads from the research supported through the supplement. This supplement opportunity is part of a larger NIH CCH initiative that seeks to build a global community of practice that will work towards trans-disciplinary solutions-driven science to address the serious impacts of climate change on health.
52
NIH
PAR-23-125
Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
2025-08-15
The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.
53
NIH
PAR-23-269
NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
2025-08-14
The NIDA Avant-Garde Award Program for HIV Research supports exceptionally creative scientists, who propose high-impact studies that open new areas of HIV research in the context of substance use and Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV in people with SUD. The term “avant-garde” refers to highly innovative ideas and/or approaches that have the potential to be transformative. Accordingly, applications responding to this FOA must propose pioneering research that aligns with the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html and is substantially different from what is currently being pursued by the principal investigator or others in the field. In essence, this funding opportunity supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV in people with SUD. Some examples of research studies include developing creative strategies to prevent HIV transmission in high-risk substance using populations, to improve outcomes of HIV and HIV-related comorbidities, and to achieve functional or sterilizing cure of HIV.
54
NIH
PAR-23-122
Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)
2026-05-07
The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.
55
NIH
PAR-23-158
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
2026-05-07
This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. This NOFO is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and studies that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-23-157.
56
NIH
PAR-23-114
Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25 Clinical Trial Not Allowed)
2025-01-17
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
57
NIH
PAR-23-168
Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
2026-05-07
The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays.
58
NIH
PAR-23-165
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
2026-05-07
This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO (PAR-23-164).
59
NIH
RFA-MH-23-331
BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
2026-03-13
Outcome-focused quality measures take the form of assessing the fraction of a given group of patients – e.g., those served by a given clinician, facility, health system, or health plan – whose outcomes meet or exceed certain specified clinical objectives. While standardized instruments for assessing patient clinical status are plentiful, there is a gap in the translation of standardized instruments of patients’ clinical status into outcome-focused measures of mental health care. Endorsement by relevant regulatory or governing bodies will facilitate implementation of these measures, for example, into clinical practice, health care quality reporting, and alternative payment programs.
60
NIH
PAR-23-171
Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
2025-05-15
The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers.
This R34 NOFO solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - Targeted BCP R01, as described in the companion NOFO (RFA-NS-23-024). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.
This NOFO solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.
63
NIH
RFA-NS-23-026
BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)
2024-10-11
This notice of funding opportunity (NOFO) supports efforts to disseminate resources for integration into neuroscience research practice. The resource(s) should be relevant to the goals of the BRAIN Initiative as outlined in the "BRAIN 2025: A Scientific Vision" and "The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures" and shared broadly to the neuroscience community. The resource(s) should address compelling needs of neuroscience researchers that are otherwise unavailable or impractical in their current form. Activities must include dissemination of an existing resource, and may include one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and/or specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community.Applications primarily focused on technology or software development and where broad dissemination is not planned to be initiated by year 2 are not responsive to this NOFO.
64
NIH
PAR-23-157
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
2026-05-07
This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” please use the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282
65
NIH
PAR-23-164
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
2026-05-07
This Funding Opportunity Announcement (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO (PAR-23-164).
66
NIH
NOT-MD-23-014
Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience Seminar Series at NIMHD-Funded Research Centers in Minority Institutions
-0001-11-30
This Notice of Special Interest (NOSI) invites applications for administrative supplements to NIMHD U54 awarded under the Research Centers in Minority Institutions (RCMI) program to support a scientific and professional development speaker series geared to undergraduate, pre-doctoral , and doctoral scholars focused on research on substance use, addiction, and/or neuroscience.
67
NIH
NOT-MD-23-008
Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities
-0001-11-30
This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.
68
NIH
RFA-MH-23-330
BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)
2026-03-13
The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers.
69
NIH
PAR-23-193
Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
2026-04-03
The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding).
70
NIH
PAS-23-173
HIV Prevention and Alcohol (R01 Clinical Trials Optional)
2026-05-07
The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.
71
NIH
PAS-23-172
HIV Prevention and Alcohol (R34 Clinical Trials Optional)
2026-05-07
The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.
72
NIH
NOT-MH-23-235
Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders
-0001-11-30
The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration’s (FDA's) guidance on natural history studies for rare disorders).
73
NIH
NOT-MH-23-236
Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders
-0001-11-30
The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pre-clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.
74
NIH
NOT-MH-23-250
Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults
-0001-11-30
The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications that include developmentally tailored research focused on adolescents and young adults (youth) related to HIV prevention and treatment. This Notice of Special Interest is a reissue of NOT-MH-20-035.
75
NIH
RFA-MH-23-295
BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)
2024-06-07
The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative notice of funding opportunity is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell- and circuit-specific tools will require extensive focused research designed to remove barriers for targeted circuit manipulation. In addition to identification and removal of barriers, the need to delineate dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cell- and circuit-specific mapping, monitoring, and manipulating tools has been developed for use in model organisms, primarily rodents, fish and flies. These cutting-edge tools are increasingly adaptable to larger mammalian brains and, more importantly, are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those that are more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of principle studies aimed at demonstrating the feasibility of using the cutting-edge approaches in humans and other mammalian species (e.g., non-human primate [NHP]/sheep/pigs).
76
NIH
PAR-23-184
Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)
2026-07-08
The Center for Inherited Disease Research (CIDR) carries out high-throughput genotyping and sequencing and supports statistical genetics services designed to 1) aid identification of genes or genetic modifications that contribute to human health and disease or 2) enhance the classification and characterization of well-phenotyped specimens by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services, and statistical genetic support. This is an NIH-wide initiative that is administered by NHGRI. Information about current services offered can be accessed via: https://cidr.jhmi.edu.
77
NIH
NOT-AA-23-011
Notice of Special Interest: Secondary Analyses of Existing Alcohol Research Data
-0001-11-30
The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research.
78
NIH
PAR-23-199
ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)
2025-05-25
NIH established a clinical genomics infrastructure to develop an openly accessible knowledgebase that promotes data sharing and provides standardized infrastructure and tools for determining the clinical relevance of genetic variants through two initiatives: the Clinical Genomics Resource (ClinGen) and the Clinical Variant Database (ClinVar) of clinical variation. ClinGen defines the clinical relevance of genes and variants for use in precision medicine and research by standardizing clinical annotation and interpretation of variants and implementing evidence-based expert consensus assertions. The purpose of this Notice of Funding Opportunity (NOFO) is to establish Expert Panels that will select genes and genomic variants associated with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Curation Expert Panels funded through this NOFO are required to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures, interfaces, tools, and informatics infrastructure.
79
NIH
NOT-GM-23-004
Notice of Special Interest (NOSI): Program Priority Areas for MOSAIC UE5 - November 2023 Application Due Date
-0001-11-30
The purpose of this Notice is to inform applicants of the scientific areas of programmatic need for the November 15, 2023 application due date for PAR-21-277 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)".
80
NIH
RFA-MH-24-280
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)
2027-02-08
The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.
81
NIH
PAR-23-178
NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)
2025-09-26
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research
82
NIH
RFA-HG-23-017
Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
2025-07-08
The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged.
83
NIH
RFA-HG-23-018
Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
2025-07-08
The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives.This R21 Notice of Funding Opportunity (NOFO) will support small research projects that can be carried out in a short period of time with limited resources. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged.
84
NIH
NOT-DA-24-010
Notice of Special Interest (NOSI): Impacts of Psychedelic and Dissociative Drug Policy Changes on Public Health Outcomes
-0001-11-30
The purpose of this notice of special interest (NOSI) is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of special interest in grant applications that examine the impact of changing state and local psychedelic and dissociative drug policies.
85
NIH
NOT-MH-23-265
Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment
-0001-11-30
The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. This NOSI is a reissue of NOT-MH-20-013.
86
NIH
NOT-MH-23-240
Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research
-0001-11-30
The purpose of this Notice is to outline priorities for providing supplemental funding to investigators and institutions with active National Institute of Mental Health (NIMH) awards that experienced significant setbacks as result of the COVID-19 pandemic, which were unable to be resolved with non-monetary options (e.g., modification to the project or re-budgeting to accomplish aims).
87
NIH
NOT-MH-23-275
Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets
-0001-11-30
The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving implementation research grant applications designed in partnership with domestic and global service providers to advance HIV prevention and treatment goals (domestically) or targets (globally). These applications should target the unique needs in jurisdictions, both in cities and rural areas, that have been disproportionally affected by the HIV epidemic in the U.S. and globally. This NOSI is a reissue of NOT-MH-20-024.
88
NIH
PAR-24-210
Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)
2026-05-18
This Notice of Funding Opportunity (NOFO) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within various care systems that provide mental health interventions and services. The ALACRITY Centers program is intended to support research that maximizes synergies across various components of the mental health research ecosystem, including new discoveries in clinical research, transformative health care technologies, advances in information science, and new federal and state mechanisms for organizing mental health care. The Centers are intended for transdisciplinary projects that could not be achieved using standard research project grant mechanisms. The ALACRITY Centers program is also expected to facilitate widespread sharing of relevant data, methods, and resources that will accelerate clinical research and practice and provide opportunities for graduate students, postdoctoral researchers, and early-career investigators to participate in transdisciplinary, T2 translational mental health research.
89
NIH
RFA-MH-24-120
Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
2024-10-18
The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. In the first phase (UG3), investigators are expected to identify potential tools and/or biomarker(s) that can predict whether a patient will differentially respond to one well-established depression treatment versus another. This could be accomplished using secondary analysis of data from completed clinical trials or using real-world clinical data, or by conducting small, efficient pilot feasibility studies to assess promising new tools or biomarkers to predict individual treatment response to a specific therapeutic for depression. In the second phase (UH3), investigators will conduct independent, prospective clinical trials to initially validate the utility of the tool/biomarker for predicting differential response to established treatments for depression. The overall goal of this NOFO is to support the testing of various tools/biomarkers as predictors of response to well-established depression treatments and halt the development of those tools that do not meet sufficient performance characteristics to justify further testing. Ultimately, tools that are successful in early stage studies could be further evaluated for future use in decision-making in clinical practice settings.
90
NIH
RFA-DA-24-006
Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Basic Experimental Studies with Humans (BESH) Required)
2024-02-15
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for basic science experiments involving humans (BESH) aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on neurobehavioral function and risk for substance use disorders (SUD) and co-occurring psychiatric disorders in people living with HIV (PLWH). As referred to in NOT-OD-18-212, BESH are “prospective basic science studies involving human participants” that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Such studies prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental processes or principles. Applicants proposing projects involving animal models or observational studies in humans should use the companion NOFO, RFA-DA-24-005.
91
NIH
PAR-23-301
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
2027-01-07
The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.
92
NIH
PAR-23-302
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
2027-01-07
The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets.
93
NIH
PAR-22-268
Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25 Clinical Trials Not Allowed)
2025-01-27
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
94
NIH
RFA-HG-23-002
Broadening Opportunities for Computational Genomics and Data Science Education (UE5 Clinical Trial Not Allowed)
2024-06-10
The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this U35 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
95
NIH
PAR-23-240
Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)
2026-05-25
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications.
96
NIH
PAR-23-229
NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)
2026-05-05
The Adolescent Brain Cognitive DevelopmentSM (ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays.
97
NIH
PAR-24-027
Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
2026-10-30
The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This notice of funding opportunity (NOFO) allows investigators to apply for access to the biospecimens from the PATH Study Information about the PATH Study and this resource may be found on the at the University of Michigan’s National Addiction & HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Research’s (ICPSR) website (https://nida.nih.gov/research/nida-research-programs-activities/population-assessment-tobacco-health-path-study/data-access).
98
NIH
RFA-DA-25-003
Cohort Studies of HIV/AIDS and Substance Use (U01 Clinical Trial Not Allowed)
2024-08-16
This initiative allows investigators to apply for access to biological samples from the ABCD Study®. More information about the ABCD Study can be found on the NIDA ABCD Study web page. Additional information about this resource is available on the NIDA funding opportunities page, under Supplemental Information for NOFOs. ABCD Study biospecimens are managed through the NIH Brain Development Cohorts (NBDC) Biorepository and Analysis Center, which offers a web portal with services related to biospecimen access. Visit the NBDC portal to query available samples using the Biospecimen Explorer, submit a Biospecimen Availability Inquiry to determine the resource availability and impact on existing samples, and learn more about this resource.
99
NIH
RFA-DA-25-014
Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
2025-08-14
The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohort studies that addresses the intersection of HIV and substance use. This program is a multidisciplinary platform to support basic, epidemiologic, and clinical research on HIV and HIV-associated co-morbidities and co-infections among populations with substance use and substance use disorders (SUDs) and to address research questions at the individual and population level. The purpose of this notice of funding opportunity (NOFO) is to support the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance use in alignment with NIH-HIV research priorities in order to inform policy or practice. Cohort sites supported under this program are required to report to and collaborate with a NIDA funded Coordinating Center, including participating in research agendas addressing NIDA’s high priority areas.
100
NIH
RFA-DA-24-026
NIDA REI: Academic Research Enhancement Award (AREA) Training a Diverse Data Science Workforce for Addiction Research (R15 Clinical Trial Not Allowed)
2024-01-24
This notice of funding opportunity (NOFO) is a part of the National Institute on Drug Abuse's (NIDA’s) Racial Equity Initiative (REI).
101
NIH
PA-23-230
PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
2024-04-05
This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2023-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA).
102
NIH
PA-23-271
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
2025-09-07
The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds, including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce.
103
NIH
RFA-MH-25-145
Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed)
2024-01-31
This Notice of Funding Opportunity (NOFO) will expand the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium. The long-term goal of SSPsyGene is to systematically characterize the function of neurodevelopmental and psychiatric disorder (NPD) risk genes, across biological scales of organization (molecular, cellular, circuit, systems/organismal). This resource will be made available for broad use by the biomedical research community.
104
NIH
NOT-AA-23-018
Notice of Special Interest (NOSI): Epidemiology and Prevention in Alcohol Research
2026-09-05
NIMH is announcing its intention to issue single source award to the Brigham and Women’s Hospital (the recipient organization awarded under RFA-MH-20-341) to support the NIMH-funded Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project. The recipient will support the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Clinical High Risk (CHR) for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CT-DPACC) which will provide management, direction, and coordination, including data processing and analysis to support the AMP SCZ CHR Clinical Trial Network (see companion NOFO (RFA-MH-24-150). The CHR Clinical Trial Network will validate the utility of drug development tools (biomarkers, digital measures, clinical outcome measures and algorithms) previously assessed in the AMP SCZ observational study. The CT-DPACC will support the efforts of the Clinical Trial Network in a 12 – 16 week Proof of Principle trial (or trials) utilizing a Phase 2 ready compound(s).
105
NIH
PAR-23-252
Alcohol Health Services Research (R34 Clinical Trial Optional)
2026-09-07
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.
106
NIH
PAR-23-251
Alcohol Health Services Research (R01 Clinical Trial Optional)
2026-09-07
Brigham and Women’s Hospital serves as the DPACC for the AMP® SCZ observational study, which established a multi-site international research network focused on recruiting individuals at CHR for schizophrenia. The DPACC required several years to develop the expertise needed to perform its functions for the overall AMP® SCZ program. To ensure the success of the Proof of Principle trial, these functions must be performed in an expeditious manner, yet the complexity of the tasks makes it impossible for an outside group to assume responsibilities and complete them in the required study timeframe. If a new group were selected to perform the functions of the CT-DPACC, it would require an impractically long amount of time to develop the expertise and resources needed to meet the goals of the project. It is essential to maintain consistent support from members of the DPACC as AMP® SCZ moves to the PoP trial. Therefore, NIMH will issue a single source award to the Brigham and Women's Hospital to meet this unique programmatic need.
107
NIH
NOT-DA-25-026
Notice of Special Interest (NOSI): Role of social function on SUD treatment and outcomes
2026-09-07
NA
108
NIH
NOT-DA-24-011
Notice of Special Interest (NOSI): HEAL Initiative: Leveraging Inpatient Medical or Surgical Hospitalizations to Improve Outcomes for People Who Use Drugs
2025-11-12
The structure of PATC3H-IN shall consist of three highly integrated components - (1) Clinical Research Centers (CRC) (each center will propose a study to be executed in at least 5 research performance sites); (2) a Coordination and Operations Center (COC); and (3) an Implementation Science Coordinating Center (ISCC).
109
NIH
PAR-23-253
Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
2026-08-13
This notice of special interest (NOSI) invites both preclinical and clinical applications to evaluate the role of social functioning in the treatment of substance use disorders (SUDs) and as potential endpoints for therapeutics development.
110
NIH
RFA-DA-25-018
Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional)
2024-08-05
This NOFO solicits applications for a single Implementation Science Coordinating Center.
111
NIH
RFA-DA-24-067
HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)
2026-01-16
The goal of this notice of funding opportunity (NOFO) is to support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk among survivors of sex trafficking. This would be accomplished through research that builds new interventions and models of care that can effectively engage survivors of sex trafficking in care for substance use disorder (SUD), HIV, trauma, and other mental health outcomes and addresses key structural and social determinants of health that contribute to risk for sexual trafficking, as well as barriers to and facilitators of escaping continued exploitation.
112
NIH
RFA-DA-24-066
HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)
2026-01-16
NA
113
NIH
RFA-DA-25-001
Addressing HIV in Highest Risk Sexual and Gender Minorities (R01 Clinical Trial Optional)
2024-08-14
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
114
NIH
RFA-DA-24-005
Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Clinical Trials Optional)
2024-02-15
Despite an evidence base of effective programs to prevent the initiation of substance use, misuse and disorder, a substantial research to practice gap exists. The goal of this initiative is to support projects that fill this research to practice gap, improving public health and responding to the opioid crisis by increasing knowledge pertaining to the delivery of prevention services. This notice of funding opportunity (NOFO) solicits applications to address understudied areas of opportunity that, if researched, could create the foundation needed to inform a prevention infrastructure for ongoing delivery and sustainment of interventions to prevent opioid and other substance misuse and use disorders. This NOFO invites projects for which preliminary or feasibility data is not available. This NOFO is a companion to RFA-DA-24-067 which solicits applications for which pilot data is available.
115
NIH
RFA-NS-24-021
HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)
2025-02-06
NA
116
NA
NA
NA
-0001-11-30
This NOFO uses the R34 grant mechanism, while RFA-MH-24-331 uses the R21 mechanism and RFA-MH-24-330 uses the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applications with preliminary data and/or those including longitudinal analysis or proposing a large-scale clinical trial should consider using the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider the R34 mechanism.
117
NIH
RFA-AA-23-004
Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional)
2024-04-18
NIAAA seeks applications aimed to address the impact of alcohol use on the most important challenges for ending HIV/AIDS pandemic. This NOFO uses the NIH Comprehensive Research Center (P60) mechanism to support research center grants to conduct a range of basic and behavioral cross-cutting, intervention, and translational research in alcohol and HIV/AIDS.
118
NIH
RFA-DA-25-058
Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
2024-02-28
The purpose of this notice of funding opportunity (NOFO) is to support the development of classic psychedelics (e.g., psilocybin, LSD), empathogens (e.g., MDMA), dissociatives (e.g., ketamine and related compounds), and other hallucinogens (e.g., ibogaine and its analogues) (henceforth psychedelics ) as new treatment options for Substance Use Disorder (SUD). There is an urgent need to develop novel treatments for SUD in light of the escalating rates of substance use, addiction, and overdose. Psychedelics may offer a new potential therapeutic use in SUD. Applications may include the evaluation of an existing psychedelic, a new formulation, or a new psychedelic compound. The application can be at a preclinical and/or clinical phase of medication development.
119
NIH
RFA-DA-25-048
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
2026-03-13
The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBC) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder
120
NIH
RFA-DA-25-047
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
2026-03-13
The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBCs) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder.
121
NIH
RFA-DA-25-013
Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
2025-03-13
The goal of this notice of funding opportunity (NOFO) is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.
122
NIH
RFA-DA-25-012
Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
2025-03-13
The goal of this notice of funding opportunity (NOFO) is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.
123
NIH
PAR-24-062
Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
2026-11-13
The purpose of this notice of this funding opportunity (NOFO) is to support translational research across epidemiology, addiction services, and prevention to, ultimately, reduce the burden of substance use on public health. This NOFO encourages research that facilitates rapid translation from one discipline to another (e.g., epidemiology to prevention); supports community/stakeholder engagement in substance use treatment and prevention clinical trials; or reduces the research to practice gap through the rapid transition from pilot study to clinical trial, or effectiveness to implementation study. The goal is to support translational research improving our ability to 1) identify and characterize malleable individual, familial, behavioral, developmental, and socio-cultural/environmental factors (within the population or precise subgroups) with the potential for multi-directional transfer of knowledge; 2) prevent initiation of substance use or progression to misuse or use disorder; and 3) maximize the efficient delivery of high-quality, personalized addiction treatment and related services to ultimately inform and facilitate real world responses designed to reduce the burden of substance use, misuse and/or addiction on the health of the population. This NOFO invites projects for which preliminary feasibility or pilot data are not available.
124
NIH
PAR-24-055
Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)
2026-06-10
This is a non-competitive funding opportunity intended, if the application is meritorious, to fund a single award to the Coriell Institute for Medical Research for the NIGMS Human Genetic Cell Repository (HGCR). The purpose of the NIGMS HGCR is to maintain the current collection of cell cultures and DNA samples and acquire, characterize, and expand high-quality cell samples and distribute cell lines and extracted DNA to qualified biomedical researchers.
125
NIH
RFA-MH-24-181
Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional)
2024-03-01
Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental illness and risk for psychopathology. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology. This NOFO seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity RFA-MH-24-180 seeks R01 grant applications proposing longer term projects with supporting preliminary data.
126
NIH
RFA-MH-24-180
Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional)
2024-03-01
Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental illness and risk for psychopathology. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology. This NOFO uses the R01 grant mechanism, whereas its companion NOFO, RFA-MH-24-181, seeks shorter, higher-risk R21 grant applications.